기사 (40건) 리스트형 웹진형 타일형 YEPBIO’s YPD-01 Targets ‘PARIS’ in Parkinson’s YEPBIO’s YPD-01 Targets ‘PARIS’ in Parkinson’s ANLBIO’s ANL-101 Targets MicroRNAs for Alzheimer’s ANLBIO’s ANL-101 Targets MicroRNAs for Alzheimer’s GNT Pharma’s Crisdesalazine Undergoing Phase 1b Clinical Trial for Alzheimer’s GNT Pharma’s Crisdesalazine Undergoing Phase 1b Clinical Trial for Alzheimer’s QuorumBio’s QAL333 Targets NLRP3 Inflammasome in Alzheimer’s QuorumBio’s QAL333 Targets NLRP3 Inflammasome in Alzheimer’s MEDIFRON Files PCT Patent Application for Treating Alzheimer’s Disease Using MDR-0214 MEDIFRON Files PCT Patent Application for Treating Alzheimer’s Disease Using MDR-0214 NEXMOS to Blaze a Trail in the Field of APTAMER NEXMOS to Blaze a Trail in the Field of APTAMER NKMAX’s SNK01, Autologous NK Cells for Alzheimer’s NKMAX’s SNK01, Autologous NK Cells for Alzheimer’s VT BIO’s VT301, Autologous Regulatory T cells (‘Tregs’) for Alzheimer’s VT BIO’s VT301, Autologous Regulatory T cells (‘Tregs’) for Alzheimer’s BeyondBio’s BEY2153 Targets Beta-Amyloid and Tau Simultaneously BeyondBio’s BEY2153 Targets Beta-Amyloid and Tau Simultaneously Isu Abxis’ ISU203, a Novel Anti-ASM Monoclonal Antibody for Alzheimer’s Isu Abxis’ ISU203, a Novel Anti-ASM Monoclonal Antibody for Alzheimer’s Peptron’s PT320, First-In-Class Candidate for Parkinson's Disease Peptron’s PT320, First-In-Class Candidate for Parkinson's Disease Kainos Medicine Receives FDA Approval of IND for Phase 2 Trial of KM-819 Kainos Medicine Receives FDA Approval of IND for Phase 2 Trial of KM-819 처음처음이전이전1234다음다음끝끝